* DarioHealth Corp DRIO.OQ DRIO.O is expected to show a
rise
in quarterly revenue when it reports results on August 8 for
the period ending June 30 2024
* The New York City-based company is expected to report a
28.6% increase in revenue to $7.914 million from $6.15 million a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for DarioHealth Corp is for
a loss
of 56 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for DarioHealth
Corp
is $5.00, above its last closing price of $0.97.
This summary was machine generated August 6 at 17:32 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)